Teva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024.
The drugmaker also said late-stage results for a new drug for schizophrenia met its primary endpoints, helping to push its New York-listed shares up more than 13%…

#abbvie#humira#medincell#teva#richardfrancis#pbmscignagroup#unitedhealthgroup#johnsonjohnsons